GAD1 and type 1 diabetes mellitus: Data from the recently completed placebo-controlled phase 2b DIAGNODE-2 trial showed that those participants with T1D who carried the HLA DR3-DQ2 haplotype benefited significantly from 3 monthly intralymphatic administrations of recombinant human GAD65 (rhGAD65) in alum (GAD-alum/Diamyd) with regard to preserving insulin-producing capacity (20), confirming observations previously reported in a large-scale meta-analysis (21).